COMPANY PROFILE

MEZZION

Explore full profile

Innovative drug development targeting rare diseases with high success potential

Fort Lee, United StatesBiotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About MEZZION

Mezzion USA is a pharmaceutical company dedicated to discovering, developing, and delivering new medicines for rare diseases. The company leverages extensive experience in drug development and clinical trials to bring hope to patients who previously had limited or no treatment options. Mezzion USA operates in the biopharmaceutical market, focusing on rare diseases, which often lack sufficient research and development due to their low prevalence. The business model revolves around identifying promising drug candidates, conducting rigorous clinical trials, and bringing successful treatments to market. Revenue is generated through the sale of these specialized medicines, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The primary clients are patients suffering from rare diseases, healthcare providers, and research institutions. Mezzion USA aims to fill a critical gap in the healthcare industry by providing innovative solutions where they are most needed.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Headquarters: Fort Lee, United States
Employees: 14
Open positions: None listed
Dealroom signal: 18.1/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Rare Diseases, Hard Tech, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jun 2025	$20M	$200M	Undisclosed	↗
EARLY VCOther financing	Apr 2023	$40M	$160M	BRV Capital Management	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

MEZZION website traffic

Latest recorded traffic for MEZZION is 4.1K monthly website visits, up 78.3% over the last three months. MEZZION's team grew 250% over the past year.

Latest monthly visits4.1K 3-month web change+78.3% 1-year team growth+250%

Monthly website visitsApr 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSuzhou Huitherapy Biomedical Technology a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs	China	Operational	—	$41M	$138M
ATAlamab TherapeuticsClinical Trial Approval in Australia	Princeton, United States	Operational
SOSovargenLeading the way in RNA therapies for brain diseases	Daejeon, South Korea	Operational
FUFuturedMeFuturedMe Inc.- A pioneer in the science of using novel protein degradation CANDDYTM Platform towards “No Patients without Medicine”-	Tokyo, Japan	Operational
HGHemu GeneA gene therapy technology developer	Ningde City, China	Operational
MOMonoclonalsDevelops novel monoclonal antibodies for rapid tests which diagnose diseases, specifically for resource poor areas	Ellsworth, United States	Operational
WTWings TherapeuticsTherapeutics for rare genetic blistering skin diseases	Berkeley, United States	Operational
BPBioTx PharmaceuticalsBiotech & Life Sciences	United Arab Emirates	Operational